Safety Study of Nebivolol for COPD Patients

Phase 3WithdrawnNCT01939990

University of Chicago

Overview

The purpose of this study is to demonstrate the safety and effectiveness of the study drug Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary Disease (COPD).

The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with documented COPD greater than age 40.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Conditions

High Blood Pressure

Interventions

PlaceboDRUG

The placebo looks like the study drug but it does not contain active ingredients.

NebivololDRUG

5 to 10mg per day

Eligibility

Sex: ALLMin age: 40 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease (COPD) Exclusion Criteria: * Asthma; Heart failur; * End stage kidney disease; * acute myocardial infarction,unstable angina, stroke or TIA within the past year; * Females who are pregnant, lactating or women of childbearing potential who are not using approved method of contraception.

Locations (1)

University of Chicago Medical Center

Chicago, Illinois, United States

Outcomes

Primary Outcomes

to assess blood pressure control

blood pressure control will be assessed per collection of research data at protocol visits.

Time frame: baseline to 4 weeks

Secondary Outcomes

to assess pulmonary function tests

pulmonary function tests will be assessed at protocol visits

Time frame: baseline to 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.